[von Hippel-Lindau disease]
Abstract:
The available diagnostic and therapeutic possibilities allow to treat successfully all manifestations of von Hippel-Lindau disease. Adenocarcinomas of the kidneys, however, still present a serious therapeutic problem due to their mostly bilateral and multifocal occurrence. Evidence that patients after bilateral nephrectomy with subsequent dialysis or transplantation would have a longer survival time than patients whose kidneys had not been removed has not been provided as yet. Partial resection or enucleation of tumors may postpone the development of metastases but does not prevent tumor formation in the remaining parts of the kidneys. Considering the late appearance of metastases, though evidence only in one of our patients, we preferred not to remove the kidney and to introduce dialysis. The availability of sonography has put the kidney into the focus od attention in this disease. Not only does sonography allow to monitor regularly members of the affected families but also to screen for the disease at routine sonographic examination of the abdomen. (Fig. 7, Ref. 15.)
Insights
Von Hippel-Lindau disease management is improving, but kidney adenocarcinomas remain challenging. Early detection via sonography aids monitoring, but surgical interventions for kidney tumors in VHL disease require careful consideration.
Area of Science:
- Oncology
- Nephrology
- Genetics
More Related Videos
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor
Published on: September 13, 2018
06:16LipidUNet-Machine Learning-Based Method of Characterization and Quantification of Lipid Deposits Using iPSC-Derived Retinal Pigment Epithelium
Published on: July 28, 2023
Related Concept Videos
Pleiotropy
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Lysosomal Hydrolases
Hedgehog Signaling Pathway
iPS Cell Differentiation
Huntington Disease l: Introduction
